Skip to content
★ Sign in to follow
KT

Kelly T. McKee Jr.

Directeur Médical
GeoVax Labs, Inc.
Insider activity · 24 months1 buy0 salesCumulative net flow
Total declarations
6
Company
1
▲ Purchases (6 ops.)
€22k
▼ Sales (0 ops.)
—

Latest filing published 08 Aug 2025 for GeoVax Labs, Inc., €635.

Filing timeline

BuySale
Kelly T. McKee Jr.

Insider track record

Disclosed buys
6
Disclosed sells
0
T+90 hit rate
75%
T+90 mean return
+181.9%

Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.

Signal history

Kelly T. McKee Jr.: trading record in brief

This profile gathers the share dealings of Kelly T. McKee Jr. in GeoVax Labs, Inc., where the filings describe the role as senior executive. We count 6 filings; the first trade dates from 4 May 2022 and the latest from 7 August 2025.

Purchases make up the whole of the open-market record (6 purchases, €22k). Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Since January 2025: 1 purchase and no sales on the market.

In size, the median ticket on the buying side is €4,033. On 1 out of 6 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The record was last updated on 8 August 2025 with an open-market purchase (€635) in GeoVax Labs, Inc. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.

Companies and markets linked to Kelly T. McKee Jr.

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations6 total
  • ▲
    Chief Medical OfficerExecutivesGeoVax Labs, Inc.
    742 USD29SEC
    1,107 shares@ US$0.672.8% of flowCommon StockSEC:0001437749-25-025690:0
    Canonical exit: 5 Nov 2025 (T+90)
  • ▲
    Chief Medical OfficerExecutivesGeoVax Labs, Inc.
    2,500 USD32SEC
    6,944 shares@ US$0.3610.5% of flowCommon StockSEC:0001437749-23-035306:0
    Canonical exit: 21 Mar 2024 (T+90)
  • ▲
    Chief Medical OfficerExecutivesGeoVax Labs, Inc.
    5,020 USD31SEC
    9,653 shares@ US$0.5224.4% of flowCommon StockSEC:0001437749-23-026935:0
    Canonical exit: 24 Dec 2023 (T+90)
  • ▲
    Chief Medical OfficerExecutivesGeoVax Labs, Inc.
    5,000 USD60SEC
    4,464 shares@ US$1.120.15% mcap32.1% of flowCommon StockSEC:0001437749-22-016072:0
    Canonical exit: 25 Sept 2022 (T+90)
  • ▲
    Chief Medical OfficerExecutivesGeoVax Labs, Inc.
    7,000 USD20SEC
    9,722 shares@ US$0.7229.7% of flowCommon StockSEC:0001437749-22-011257:0
    Canonical exit: 3 Aug 2022 (T+90)
  • ▲
    Chief Medical OfficerExecutivesGeoVax Labs, Inc.
    3,549 USD16SEC
    4,999 shares@ US$0.7114.9% of flowCommon StockSEC:0001437749-22-011137:0
    Canonical exit: 2 Aug 2022 (T+90)

6 of 6 declarations